An Open-Label, Single Dose, Relative Bioavailability Study of Solid Formulations in Fed and Fasted Conditions Followed by a Repeated Dose Study of a Selected Solid Formulation of JNJ-39393406 in Healthy Male Subjects
Latest Information Update: 31 Oct 2014
At a glance
- Drugs JNJ 39393406 (Primary)
- Indications Alzheimer's disease; Schizophrenia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Janssen Research & Development
- 24 Nov 2013 New trial record